Observation on the Effect of Different Administration Methods of Tirofiban in the Treatment of Early-stage Non-large Vessel Occlusion Cerebral Infarction
Objective:To compare the safety and clinical efficacy of combined arteriovenous and intravenous tirofiban in the treatment of early non-vascular occlusive cerebral infarction.Methods:From December 2018 to December 2023,63 patients with non-large vessel occlusion cerebral infarction treated in the Department of Neurointervention of Luoyang Central Hospital were included.According to whether cerebral angiography was performed,they were divided into study group(32 patients)and control group(31 patients).The study group was treated with arteriovenous combined with tirofiban,while the control group was treated with tirofiban alone.The safety,NIHSS score and mRS score at 90 days after treatment were compared between the two groups.Results:There was no significant difference in the rate of bleeding in other parts and the rate of neurological deterioration between the two groups(P>0.05),and the incidence of symptomatic intracranial hemorrhage within 48 hours after intervention and the 90-day mortality rate were zero in both groups.The NIHSS scores of the study group at 24 h and 7 days after intervention were lower than those of the control group(P<0.05).After 90 days,the proportion of patients with mRS score≤2 in the study group was higher than that in the control group(P<0.05).Conclusion:For patients with early-stage non-vascular occlusive cerebral infarction,arteriovenous combined with tirofiban is more effective than tirofiban alone,which can improve NIHSS and MRS scores,and improve the daily living ability.
NETL
NSTL
万方数据
